Generated by AI
Bioventus Inc. Class A Common Stock represents Bioventus Inc., a medical technology company focused on developing and commercializing products for musculoskeletal care and active healing. Bioventus serves patients and healthcare providers with orthobiologic and restorative solutions designed to support bone healing, pain treatment, and recovery from a range of orthopedic conditions. Its current business is organized around active healing therapies, surgical solutions, and related products used in both U.S. and international markets. The company’s portfolio includes therapies such as hyaluronic acid injections for osteoarthritis, peripheral nerve stimulation devices, bone graft substitutes, and ultrasound-based fracture-healing technologies. Bioventus operates as a specialized healthcare company within the broader medical device sector, with offerings aimed at non-surgical and surgical treatment settings.
Website4721 Emperor Boulevard
Durham, NC, 27703
United States
The latest articles about BVS.
Bioventus walked into this Q3 2026 report with a stock already under pressure, and it just took another hit. Shares closed at US$13.15 before the release and then slumped about 17% to roughly US$10.95 as investors reacted in real time. The headline result looked steadier than the price suggests. Management kept full year adjusted earnings per share guidance unchanged, while adjusted EBITDA margin held at a firm 20%. The issue was on the top line, as full year revenue guidance moved lower...
Summary of Nov 2's posts. Generated by AI.
Summary of May 19's posts. Generated by AI.
Summary of May 7's posts. Generated by AI.
Investors talking about BVS also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.